What is the clinical evidence from this study?

Study design: Other. Population: Doxorubicin-induced cardiotoxicity. Intervention: Metformin and sitagliptin vs. DOX group. Primary outcome: Cardiac protection (serum LDH, CK-MB, cardiac MDA, total nitrites/nitrates, SOD activity, histopathology, COX-2, iNOS, caspase-3) (p=< 0.05).

January 1, 2015Journal of ToxicologyOpen Access

Effect of Metformin and Sitagliptin on Doxorubicin-Induced Cardiotoxicity in Rats: Impact of Oxidative Stress, Inflammation, and Apoptosis

Q: What are the key findings of this study?

Pretreatment with metformin or sitagliptin produced significant cardiac protection against doxorubicin-induced cardiotoxicity in rats (P < 0.05).

View Full Paper

Ask AI

Bookmark

Key result

Pretreatment with metformin or sitagliptin produced significant cardiac protection against doxorubicin-induced cardiotoxicity in rats (P < 0.05).

Why the study?

Does pretreatment with metformin or sitagliptin prevent doxorubicin-induced cardiotoxicity in rats?

Population

Rats in a model of doxorubicin-induced cardiotoxicity (single dose 15 mg/kg i.p. at the fifth day)

Comparison

Metformin or sitagliptin vs Doxorubicin alone (DOX group)

Design

Preclinical

Follow-up

7 days

Authors

MKMina KelleniMinia University EAEntesar F. AminMinia University AAAly M. AbdelrahmanSultan Qaboos University

Discussion

Member takes

Implication

No immediate clinical implications for doxorubicin-treated patients; leaves open translation of cardioprotection from rat models to humans.

Structured PICO

Does pretreatment with metformin or sitagliptin prevent doxorubicin-induced cardiotoxicity in rats?

Population

Rats in a model of doxorubicin-induced cardiotoxicity treated for seven days.

Intervention

Metformin (250 mg/kg dissolved in DW p.o. for seven days) or sitagliptin (10 mg/kg dissolved in DW p.o. for seven days)

Comparator

Doxorubicin alone (DOX group)

Outcome

Cardiac protection measured by serum levels of LDH and CK-MB, cardiac MDA, total nitrites and nitrates, cardiac SOD activity, histopathological features, and immunohistochemical expression of COX-2, iNOS, and caspase-3surrogate

Main Result

p-value: p=< 0.05

Metformin and sitagliptin demonstrated significant cardioprotective effects against doxorubicin-induced cardiotoxicity in a rat model, suggesting potential utility in diabetic patients receiving doxorubicin.

Cite This Study

Kelleni et al. (2015) studied Doxorubicin-induced cardiotoxicity. Metformin and sitagliptin vs. DOX group was evaluated on Cardiac protection (serum LDH, CK-MB, cardiac MDA, total nitrites/nitrates, SOD activity, histopathology, COX-2, iNOS, caspase-3) (p=< 0.05). Pretreatment with metformin or sitagliptin produced significant cardiac protection against doxorubicin-induced cardiotoxicity in rats (P < 0.05).

synapsesocial.com/papers/6a7794c8d3a6aa87c6bdd5ce https://doi.org/10.1155/2015/424813

View Full Paper

Ask AI

Bookmark

Implication

No immediate clinical implications for doxorubicin-treated patients; leaves open translation of cardioprotection from rat models to humans.

Effect of Metformin and Sitagliptin on Doxorubicin-Induced Cardiotoxicity in Rats: Impact of Oxidative Stress, Inflammation, and Apoptosis

Discussion

Member takes

Implication

Structured PICO

Main Result

Cite This Study

Effect of Metformin and Sitagliptin on Doxorubicin-Induced Cardiotoxicity in Rats: Impact of Oxidative Stress, Inflammation, and Apoptosis

Discussion

Member takes

Implication

Structured PICO

Main Result

Cite This Study

Also Consider

Also Consider